BioNxt Solutions Secures Chaperone Technology to Advance Oral Drug Delivery

BioNxt Solutions Inc., a Vancouver-based bioscience company, announced a non-binding letter of intent to acquire chaperone technology for oral dissolvable applications. The move is expected to enhance their oral dissolvable thin-film (ODF) platform through improved drug stability and absorption efficiency. This technology targets neurological and chronic diseases, promising better drug delivery performance without chemical modification of drugs.

CEO Hugh Rogers emphasized the strategic importance of this acquisition for reformulating drugs into fast-dissolving formats, particularly for neurological therapies. The chaperone technology aims to ensure consistent absorption and patient adherence. BioNxt aims to advance its proprietary ODF platform, enhance drug stability during storage and use, and expand its intellectual property portfolio.